Overview

Pharmacokinetics and Pharmacodynamics of Oral Transmucosal Dexmedetomidine.

Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
0
Participant gender:
Female
Summary
Oral trans-mucosal administration is relatively easy and convenient, it also reduces first pass metabolism and has been used successfully for fentanyl, ketamine, and midazolam premedication.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Assiut University
Treatments:
Dexmedetomidine
Criteria
Inclusion Criteria:

- ASA physical status I - II.

- Aged between 20 and 60 years.

- Scheduled for modified radical mastectomy

Exclusion Criteria:

- Cardiac disease.

- Hepatic disease.

- Renal disease.

- History of alcohol or drug abuse.

- Patients with a known allergy to the study drug